An International Phase 2 Study Of SU011248 In Patients With Advanced / Metastatic Gastric Cancer Failing Chemotherapy

• Best Overall Response [ Time Frame: From start of study treatment until Day 28 of Cycle 1, Day 28 of Cycles thereafter ] [ Designated as safety issue: No ]
• Objective Response (Complete Response (CR) or Partial Response (PR)) [ Time Frame: From start of study treatment until Day 28 of Cycle 1, Day 28 of Cycles thereafter ] [ Designated as safety issue: No ]

• Clinical Benefit Response (CBR)-Complete Response (CR), Partial Response (PR) or Stable Disease (SD) With Duration ≥ 24 Weeks [ Time Frame: From start of study treatment until Day 28 of Cycle 1, Day 28 of Cycles thereafter or clinical benefit response for at least 24 weeks on study ] [ Designated as safety issue: No ]
• Duration of Response (CR or PR) [ Time Frame: Day 28 of Cycle 1 and Day 28 of Cycles thereafter or death due to cancer ] [ Designated as safety issue: No ]
• Progression-Free Survival [ Time Frame: From start of study treatment until Day 28 of Cycle 1, Day 28 of Cycles thereafter or death ] [ Designated as safety issue: No ]
• Time to Tumor Progression (TTP) [ Time Frame: From start of study treatment until Day 28 of Cycle 1, Day 28 of Cycles thereafter ] [ Designated as safety issue: No ]
• Overall Survival [ Time Frame: From start of study treatment until death ] [ Designated as safety issue: No ]

The study consisted of two parts. In Part 1 the study enrolled 38 patients (Step 1 Simon 2 step design) after which Step 2 was opened and the total enrollment target for the study (n=63) was exceeded due to a rapid enrollment (78 patients were entered). Part 2 of the study did not open due to the final overall insufficiency of efficacy observed in 78 patients. Sunitinib (SU011248) was administered orally daily for 4 weeks followed by a 2-week rest at a starting dose of 50 mg with provision for dose reduction based on tolerability. All patients received repeated cycles of sunitinib until disease progression, occurrence of unacceptable toxicity, or other withdrawal criteria were met. After discontinuation of treatment, patients were followed up in order to collect information on further antineoplastic therapy and survival.

Inclusion Criteria:

• Gastric or gastroesophageal junction adenocarcinoma cyto/histologically documented
• Disease progression/ recurrence after treatment with one prior single agent or combination chemotherapy regimen for advanced / metastatic disease (last dose at least 4 wks before study entry). Patients may have also received prior adjuvant therapy if recurrence occurred > 6 months after adjuvant therapy completion
• Evidence of measurable disease by radiographic technique
• Adequate organ function.

Exclusion Criteria:

• Clinically relevant ascites (i.e. requiring paracentesis)
• Severe weight loss
• NCI CTCAE Grade 3 hemorrhage <4 weeks of starting study treatment
• Diagnosis of second malignancy within last 3 years
• History of or known brain metastases, spinal cord compression, or carcinomatous meningitis
• Known HIV
• Serious acute or chronic illness
• Current treatment on another clinical trial
• Pregnant or breastfeeding